Blue Tower Asset Management, an asset management company, released its third-quarter 2024 investor letter. A copy of the ...

Advt The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi's consumer ...

Four East Carolina University alumni were honored Friday night for their service to their country, including a U.S.

The sale of a controlling 50-percent stake in Opella to CD&R values the maker of France's leading painkiller, Doliprane, at 16 billion euros ($17.4 billion), Sanofi said. "Sanofi and CD&R announce ...

The French pharmaceutical group’s board is scheduled to meet to discuss the planned transaction and finalize measures with CD&R to protect jobs and local plants, the people said, asking not to ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

French pharmaceutical group Sanofi and US private equity firm Clayton Dubilier & Rice (CD&R) have entered exclusive negotiations regarding the partial takeover of Sanofi subsidiary Opella.

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton ...